MENU
JUL 7, 2020 Opens: 6:00 AM - 12:00 PM PT

Fluidigm Infectious Disease and Oncology Virtual Summit

Fluidigm technologies are integral to supporting current progress in cancer, immunology and infectious disease research. Fluidigm has also developed new tools for SARS-CoV-2 detection and diagnostics.

You’ll hear from our lineup of exceptional speakers on their latest findings in infectious disease, oncology or immuno-oncology research. Scroll down to see the speakers.

During this half-day virtual event from 6:00am -12:00pm PT we invite you to:

  • Hear about new exciting instrument and reagent products in booths and from product introduction sessions in meeting rooms.

  • Visit booths to watch a video, browse publication highlights, access resources and chat with us to learn how Fluidigm mass cytometry, microfluidics and laser capture detection technologies and services provide unique solutions to difficult research problems.

  • Discover our high-throughput microfluidics-based solutions for viral detection including the Advanta™ DX SARS-CoV-2 RT-PCR Assay, our new extraction-free saliva-based EUA IVD for SARS‑CoV‑2.

  • Join us for the unveiling of a new Fluidigm product—an automated sample preparation system specifically designed to improve flow and mass cytometry workflows.

  • Learn about the novel AccuLift™ Laser Capture Microdissection System, which enables researchers to capture regions or single cells within the tumor microenvironment for spatial biology insights and to unlock unique molecular signatures.

In the current pandemic, Fluidigm is here to help in every way we can to make meaningful advances in the fight against COVID-19. Learn more about our COVID-19 research and detection solutions at this insightful event, including the June 12 announcement of our Emergency Use Authorization (EUA) filing with the U.S. Food and Drug Administration (FDA) for an extraction-free saliva-based test for high-throughput detection of the SARS‑CoV‑2 virus.

We look forward to meeting you!

 

For Research Use Only. Not for use in diagnostic procedures.

Fluidigm has filed for Emergency Use Authorization with the FDA. The test has been validated by Fluidigm, but the FDA’s independent review of this validation is pending.

The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in saliva specimens from individuals suspected of COVID-19 by their health care provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high-complexity tests, or by similarly qualified non-U.S. laboratories.

The Advanta Dx SARS-CoV-2 RT-PCR Assay is the subject of an EUA filing with the FDA. The FDA may require additional data, validation and/or testing, and may not ultimately provide authorization. An EUA, if granted, does not constitute FDA clearance or approval, but would allow use by authorized laboratories only while the EUA is in effect.

Information in this publication is subject to change without notice. Patent and license information: fluidigm.com/legal/notices. Trademarks: Fluidigm, the Fluidigm logo, AccuLift and Advanta are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. ©2020 Fluidigm Corporation. All rights reserved. 06/2020


Speakers

Show Resources
You May Also Like
JUL 29, 2020
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUL 29, 2020
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Immuno-Oncology & Cancer Biology The rapid development of immuno-oncology therapies has transformed the cancer treatment landscape. Discovering safe, potent, and persistent immune cell p...
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 08, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 1st Annua...
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to announce our 9th Annual Genetics Virtual Week held on April 20-22, 2021! Genetics Virtual Week 2021 will offer a multi-day content-rich program combining stellar exper...
SEP 23, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 23, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots and the Cell Biology Planning Committee are please to announce the 4th Annual Cell Biology Virtual Event, providing an opportunity to discuss recent discoveries in biological researc...
OCT 07, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
OCT 07, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 8th Annual Cancer Research and Oncology Virtual Event! This 2-day event will take place on October...
Agenda
  • Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology
    JUL 07, 2020 11:00 AM PDT
    Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology
    Hiroyoshi Nishikawa, MD, PhD
    Professor, National Cancer Center, Japan
  • Identification of human immune cell subtypes most vulnerable to IL-1β-induced inflammatory signaling using mass cytometry
    JUL 07, 2020 10:30 AM PDT
    Identification of human immune cell subtypes most vulnerable to IL-1β-induced inflammatory signaling using mass cytometry
    Hema Kothari, PhD
    Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia
  • Visualization and Analysis of High-Parameter CyTOF® Data with FCS Express in Record Time
    JUL 07, 2020 10:00 AM PDT
    Visualization and Analysis of High-Parameter CyTOF® Data with FCS Express in Record Time
    David Novo, Phd
    President, De Novo Software
  • Evaluating tumor-immune cell interactions in human lung cancer using multiparametric and spatially resolved tissue analysis
    JUL 07, 2020 9:30 AM PDT
    Evaluating tumor-immune cell interactions in human lung cancer using multiparametric and spatially resolved tissue analysis
    Kurt Schalper, MD, PhD
    Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine
  • Mass cytometry in vaccine development: utility and considerations
    JUL 07, 2020 9:00 AM PDT
    Mass cytometry in vaccine development: utility and considerations
    Patrick Reeves, PhD
    Instructor in Medicine, Massachusetts General Hospital
  • JUL 07, 2020 8:00 AM PDT
    Development of an extraction-free, saliva-based workflow for SARS-CoV-2 detection with the Biomark™ HD platform
    David King, PhD
    Vice President, R&D and Product Management, Genomics, F...
    Richard Head, MS
    Director, Genome Technology Access Center, McDonnell Ge...
  • Deciphering T cell heterogeneity in humans through analysis of antigen-specificity
    JUL 07, 2020 7:30 AM PDT
    Deciphering T cell heterogeneity in humans through analysis of antigen-specificity
    Evan Newell, PhD
    Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
  • Deep immunophenotyping of cancer microenvironments by Imaging Mass Cytometry™
    JUL 07, 2020 6:30 AM PDT
    Deep immunophenotyping of cancer microenvironments by Imaging Mass Cytometry™
    Noel de Miranda, PhD
    Principal Investigator, Leiden University Medical Center
  • Single-cell mapping of human brain cancer reveals tumor-driven education of tumor-associated leukocytes
    JUL 07, 2020 6:00 AM PDT
    Single-cell mapping of human brain cancer reveals tumor-driven education of tumor-associated leukocytes
    Burkhard Becher, PhD
    Professor and Chairman, Institute of Experimental Immunology, University of Zurich
  • Single-cell mapping of human brain cancer reveals tumor-driven education of tumor-associated leukocytes
    JUL 07, 2020 6:00 AM PDT
    Single-cell mapping of human brain cancer reveals tumor-driven education of tumor-associated leukocytes
    Burkhard Becher, PhD
    Professor and Chairman, Institute of Experimental Immunology, University of Zurich
  • Deep immunophenotyping of cancer microenvironments by Imaging Mass Cytometry™
    JUL 07, 2020 6:30 AM PDT
    Deep immunophenotyping of cancer microenvironments by Imaging Mass Cytometry™
    Noel de Miranda, PhD
    Principal Investigator, Leiden University Medical Center
  • Deciphering T cell heterogeneity in humans through analysis of antigen-specificity
    JUL 07, 2020 7:30 AM PDT
    Deciphering T cell heterogeneity in humans through analysis of antigen-specificity
    Evan Newell, PhD
    Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
  • JUL 07, 2020 8:00 AM PDT
    Development of an extraction-free, saliva-based workflow for SARS-CoV-2 detection with the Biomark™ HD platform
    David King, PhD
    Vice President, R&D and Product Management, Genomics, F...
    Richard Head, MS
    Director, Genome Technology Access Center, McDonnell Ge...
  • Mass cytometry in vaccine development: utility and considerations
    JUL 07, 2020 9:00 AM PDT
    Mass cytometry in vaccine development: utility and considerations
    Patrick Reeves, PhD
    Instructor in Medicine, Massachusetts General Hospital
  • Evaluating tumor-immune cell interactions in human lung cancer using multiparametric and spatially resolved tissue analysis
    JUL 07, 2020 9:30 AM PDT
    Evaluating tumor-immune cell interactions in human lung cancer using multiparametric and spatially resolved tissue analysis
    Kurt Schalper, MD, PhD
    Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine
  • Visualization and Analysis of High-Parameter CyTOF® Data with FCS Express in Record Time
    JUL 07, 2020 10:00 AM PDT
    Visualization and Analysis of High-Parameter CyTOF® Data with FCS Express in Record Time
    David Novo, Phd
    President, De Novo Software
  • Identification of human immune cell subtypes most vulnerable to IL-1β-induced inflammatory signaling using mass cytometry
    JUL 07, 2020 10:30 AM PDT
    Identification of human immune cell subtypes most vulnerable to IL-1β-induced inflammatory signaling using mass cytometry
    Hema Kothari, PhD
    Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia
  • Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology
    JUL 07, 2020 11:00 AM PDT
    Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology
    Hiroyoshi Nishikawa, MD, PhD
    Professor, National Cancer Center, Japan
Speakers

  • Burkhard Becher, PhD
    Professor and Chairman, Institute of Experimental Immunology, University of Zurich
    Biography
      Burkhard Becher studied Biology at the University of Cologne in Germany and specialized in Molecular Genetics and Biochemistry. In 1995, for his graduate studies he went to the Montreal Neurological Inst. at McGill University in Canada to train in Neuroimmunology with Jack Antel. His work focused on the role of microglia cells as brain-resident myeloid cells capable of instructing self-reactive T cells in the context of autoimmune neuro-inflammation. In 1999 he joined the lab of Randy Noelle at the Dartmouth Medical School to extend his work to in vivo models and transgenic mice. In 2003, he was recruited as Assistant Professor to the Neurology Department at the University Hospital of Zurich. There he continued to define the cytokine networks in inflammation. In 2008, he became full professor and chairman at the Institute of Experimental Immunology at the University of Zurich and heads the Unit for Inflammation Research.
    • Richard Head, MS
      Director, Genome Technology Access Center, McDonnell Genome Institute, Washington University School of Medicine, St. Louis
      Biography
        Richard Head is a Professor of Genetics and Pathology & Immunology at Washington University School of Medicine in St. Louis. He is also the Director of the Genome Technology Access Center at the McDonnell Genome Institute, where he oversees both research and clinical genomics. Before coming to Washington University, Head was an Associate Research Fellow at Pfizer in the Inflammation & Immunology and Indications Discovery research units.
      • David King, PhD
        Vice President, R&D and Product Management, Genomics, Fluidigm
        Biography
          David is VP, R&D Genomics at Fluidigm where he is responsible for innovation and development of microfluidic-based products across research and translational genomic, proteomic and single-cell applications. Prior to joining Fluidigm, David was EVP, Product Development at IntegenX, a company focused on integration of fluidics, optics, and biochemistry in DNA-based human identity testing. David led collaborations with the FBI, Scotland Yard and many other organizations worldwide to develop a marketplace for IntegenX products. Previously, David was VP of Product Development at Affymetrix, where he led introduction of next-generation instrument platforms and genome and transcriptome analysis products. David also served as VP, R&D and Operations at Guava Technologies, where he commercialized research and clinical flow cytometry instrument platforms and applications and led expansion of Guava's international service and support organization. David is a named inventor on 36 granted and 11 pending U.S. patents. He holds a PhD from Stanford University and a BSc honors degree from University of New South Wales, Australia.
        • Hema Kothari, PhD
          Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia
          Biography
            Hema Kothari is currently Research Assistant Professor in the Cardiovascular Medicine Division, Department of Medicine, at the University of Virginia (UVA), Charlottesville. She received her PhD in biochemistry and molecular biology from Central Drug Research Institute in India in 2008. She received post-doctoral training in the laboratory of Dr. L.V. Rao at the University of Texas Health Science Center in Tyler, Texas. During her training in the field of coagulation and thrombosis, she published several important papers on the regulation of tissue factor coagulant activity in high-impact, peer-reviewed journals. She successfully competed for an American Heart Association (AHA) post-doctoral fellowship (2011-2013) followed by an AHA Scientist Development award (2013-2017). To pursue her goal to be a translational researcher in the area of cardiovascular diseases (CVD), she joined the Coleen McNamara Lab as an instructor in 2014. In the past five years, she has extended her expertise in cardioimmunology and inflammation. Her research is focused on developing strategies for personalized medicine for CVD and other inflammatory disorders. She uses her expertise in mass cytometry to identify unique immune signatures associated with therapy response, discover biomarkers for early prediction of patients at risk for adverse side-effects and gain mechanistic insights into disease pathology. She recently secured the investigator-initiated research award from Pfizer for an ancillary study to an approved clinical trial testing efficacy of anti-CD22 antibody therapy for childhood B cell acute lymphocytic leukemia. She was also awarded the UVA Manning Fund for COVID-19 Research for her proposed work on understanding immune-inflammatory mechanisms associated with disease severity and mortality in COVID-19.
          • Noel de Miranda, PhD
            Principal Investigator, Leiden University Medical Center
            Biography
              Noel de Miranda is a Principal Investigator in the Department of Pathology at the Leiden University Medical Center and is Project Leader for the Immunogenomics group. His group aims to develop innovative therapies that are focused on stimulating a patient's immune system to recognize and eliminate cancer cells. Currently their research focuses on developing neoantigen-targeted therapies for patients diagnosed with cancers with low mutational burden, deep immuno-phenotyping of colorectal and pancreatic cancers and discovering immune cell subsets with anti-tumor activity. De Miranda received his PhD in October, 2010, from Leiden University. In 2015, he received a Lisa Fund award for his research on early-onset, late-stage colorectal cancer (CRC). In September, 2019, he received a European Research Council (ERC) Starting Grant for promising young researchers. He is a previous holder of the Fight Colorectal Cancer-Michael's Mission-AACR Fellowship for research in young-onset CRC (2015), a Dutch Cancer Society/Alpe d'HuZes Young Investigator/Bas Mulder Award (2015) and a VENI fellowship for most promising young researchers in the Netherlands (2016).
            • Evan Newell, PhD
              Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
              Biography
                Evan Newell is an Associate Professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center. He completed his BSc in immunology at McGill University and PhD in physiology at the University of Toronto. As a postdoc at Stanford University with Mark Davis he worked on biophysical aspects of T cell antigen recognition and initiated the use of mass cytometry for the study of human T cell responses. He was a principal investigator at the Singapore Immunology Network (SIgN), where his lab applied and developed novel approaches for identifying and thoroughly characterizing antigen-specific T cells. At Fred Hutch in Seattle, a major goal of the Newell Lab is to identify useful biomarkers of clinical outcomes in the context of human infection, vaccines and cancer.
              • Hiroyoshi Nishikawa, MD, PhD
                Professor, National Cancer Center, Japan
                Biography
                  Professor Hiroyoshi Nishikawa is Division Chief of Cancer Immunology at the Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC) at the National Cancer Center Japan and a Professor of Immunology at Nagoya University Graduate School of Medicine. Throughout his career his research has focused on tumor biology, tumor therapeutics and immunology. Currently his group aims to comprehensively investigate immune cells such as CD4+, CD8+ T cells and macrophages, cancer cells and environmental factors to clarify the molecular mechanisms that control immune balances in a tumor microenvironment. Nishikawa is an author of two books, Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies and Regulatory T Cells, in addition to numerous research publications. Nishikawa completed his medical and PhD graduate degree from Mie University. He was a research fellow at the Memorial Sloan Kettering Cancer Center and in 2012 took a position as Adjunctive Associate Professor at the Roswell Park Comprehensive Cancer Center.
                • David Novo, Phd
                  President, De Novo Software
                  Biography
                    David received his PhD from UCLA in Biophysics. Since that time, David has been leading the team at De Novo Software in creating cutting edge data analysis tools. David is a member of the ISAC data standards task force and continues to publish papers and regularly speaks at scientific meeting on topics regarding data analysis of flow cytometry data.
                  • Patrick Reeves, PhD
                    Instructor in Medicine, Massachusetts General Hospital
                    Biography
                      Patrick Reeves is an Instructor in medicine at Harvard Medical School and a Team Leader in the Vaccine and Immunotherapy Center at Massachusetts General Hospital. His research focuses on understanding immune responses in pathological processes in the areas of infectious disease and immuno-oncology. He and his team utilize a blend of standard and high-parameter assays and tailored data analysis methods to develop vaccine and immune modulation strategies.
                    • Kurt Schalper, MD, PhD
                      Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine
                      Biography
                        Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes molecular diagnostics, quantitative pathology and cancer biomarkers. He is an Assistant Professor of Pathology at Yale University where he leads a research team focusing on cancer immunology and immunotherapy of lung and colorectal malignancies. Dr. Schalper is the Director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center. This unit supports high quality translational research in immuno-oncology through standardized analyses of biomarkers and cross-integration with other Yale resources. These efforts could open new opportunities for biomarker discovery, identification of targets and patient selection for novel anti-cancer therapies.
                      Meeting Room Agenda

                       

                      Time (PT)

                      Speaker

                      Title

                      Institution

                      Talk Title

                      6:006:30

                      Nick Jordan

                      Field Applications Specialist, Genomics

                      Fluidigm

                      Detection and characterization of viral pathogens with microfluidics-based genomic analysis

                      6:30‒7:00

                      Jordan Moore

                      Senior Field Applications Manager, Genomics

                       

                      Fluidigm

                      Advanta™ Dx SARS-CoV-2 RT-PCR Assay for high-throughput COVID-19 diagnostic testing with saliva for use with FDA EUA

                       

                      7:00‒7:30

                      Noah Saederup, PhD

                      Senior Product Manager, Maxpar Reagents

                      Fluidigm

                      Easy, flexible and comprehensive:
                      the Maxpar® Direct™ family of immune profiling assays

                      7:30‒8:00

                      Shariq Mujib, PhD

                       

                      Thiru Selvanantham, PhD

                      Product Development Scientist

                      Product Manager, Mass Cytometry

                      Fluidigm

                      Expanding the Maxpar® Direct Immune Profiling Assay™ from 30 to 44 markers

                      8:00‒8:30

                      Alan Carpino

                      Director, LCM Business Development

                      Fluidigm

                      Capture Down to a Single Cell – AccuLift Laser Capture Microdissection Portfolio

                      8:30‒9:00

                      Teri Oldaker, BS

                      Michelle Poulin, PhD

                       

                      Principle Consultant

                      Senior Manager, Mass Cytometry Field Applications

                      Oldaker Consulting

                      Fluidigm

                       

                      Sample preparation for flow cytometry: practical considerations.

                      Flow Conductor™: a sample preparation system for flow and mass cytometry

                      9:00–9:30

                      Steve Kain, PhD

                      Director, Product Management

                      Fluidigm

                      Detection of human and viral full-length RNA using a nanoscale microfluidic platform

                      9:30–10:00

                      Rusk Malladi, MS

                      Senior Marketing Manager, Microfluidics

                      Fluidigm

                      Advanta Dx SARS-CoV-2 RT-PCR Assay for high-throughput COVID-19 diagnostic testing with saliva for use with FDA EUA

                      10:00–10:30

                      Michelle Poulin, PhD

                      Senior Manager, Mass Cytometry Field Applications

                      Fluidigm

                      CyTOF for all: the top eight reasons to use mass cytometry for your project

                      10:30–11:00

                      Noah Saederup, PhD

                      Senior Product Manager

                      Fluidigm

                      Easy, flexible and comprehensive:
                      The Maxpar® Direct™ family of immune profiling assays

                      11:00–11:30

                      Alan Carpino

                      Director, LCM Business Development

                      Fluidigm

                      Capture Down to a Single Cell – AccuLift Laser Capture Microdissection Portfolio

                      11:30–12:00

                      Teri Oldaker, BS

                      Michelle Poulin, PhD

                       

                      Principle Consultant

                      Senior Manager, Mass Cytometry Field Applications

                      Oldaker Consulting

                      Fluidigm

                       

                      Sample preparation for flow cytometry: practical considerations.

                      Flow Conductor™: a sample preparation system for flow and mass cytometry

                      About Us

                      At Fluidigm, we empower our customers to reveal meaningful insights in health and disease, identify actionable markers to inform life decisions and accelerate the development of more effective therapies. Fluidigm develops, manufactures, and markets research products for life science analytical and preparatory systems for use in mass cytometry, high-throughput genomics, and single cell genomics applications. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide.

                      Help

                      General LabRoots Questions

                      email support@labroots.com  

                      Virtual Events and Webinars

                      Supported Configurations

                      • Operating System Internet Explorer Firefox Chrome Safari
                        Vista IE8+ FF10+ Chrome15+
                        Windows 7 IE8+ FF10+ Chrome15+
                        Windows 8 IE10 FF10+ Chrome15+
                        Mac OS X   FF10+ Chrome15+ Safari5.1+
                      • Cookie settings: session cookies enabled
                      • Browser configuration must have JavaScript enabled
                      • Adobe Flash player 10.2 or later

                      To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                      Internet Connection

                      • A minimum of 100Kbps is recommended for audio-only events
                      • A minimum of 300Kbps is recommended for speaker on-video events

                      Computer Equipment

                      • Screen Resolution: Minimum 1024x768
                      • Video Card: 65,000 colors minimum
                      • Sound card and speakers (or headphones) for hearing webcast in full format
                      • Audio Card: 16-bit minimum
                      • RAM: 512MB of free RAM

                      Firewall Protocol

                      • HTTP on port 80 or HTTPS on port 443
                      • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                      • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                      Work-At-Home Attendees

                      • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                      For A Seamless Experience

                      When using a mobile device, FREE Mobile Apps are available:

                      - For viewing Webinars:

                      - For viewing Virtual Events

                      Attendee Guide

                      • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                      Virtual Event and Webinar Support:

                      Continuing Education (CME/CE) Support

                      Loading Comments...
                      Show Resources
                      Attendees
                      • See more